modelMephenytoin

Diagram of Mephenytoin

Extends from Pharmacolibrary.Drugs.ATC.N.N03AB04.

Information

name:Mephenytoin
ATC code:N03AB04
route:oral
compartments:1
dosage:100mg
volume of distribution:0.7L
clearance:40mL/min
other parameters in model implementation

Mephenytoin is an anticonvulsant medication belonging to the hydantoin class, historically used for the treatment of epilepsy and other seizure disorders. Due to the risk of severe adverse effects such as aplastic anemia, it is not commonly used or approved for clinical practice today.

Pharmacokinetics

Estimated pharmacokinetic parameters for adult healthy individuals, as no robust published PK parameters were found. Estimates are based on known metabolism (hepatic, CYP2C19), structural similarity to phenytoin, and limited historical reports.

References

  1. Sohn, DR, et al., & Chiba, K (1992). Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clinical pharmacology and therapeutics 52(2) 160–169. DOI:10.1038/clpt.1992.125 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1505151

  2. Wedlund, PJ, et al., & Wilkinson, GR (1985). Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. The Journal of pharmacology and experimental therapeutics 234(3) 662–669. PUBMED:https://pubmed.ncbi.nlm.nih.gov/4032286

  3. Balian, JD, et al., & Flockhart, DA (1995). The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clinical pharmacology and therapeutics 57(6) 662–669. DOI:10.1016/0009-9236(95)90229-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7781266

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)